STOCK TITAN

MapLight Therapeutics (NASDAQ: MPLT) holder plans sale of 33,605 shares

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

MapLight Therapeutics, Inc. reports that Anatol Kreitzer has filed a notice to sell up to 33,605 shares of MapLight voting common stock through Morgan Stanley Smith Barney LLC, with an aggregate market value of 1273966.00, around July 15, 2026 on Nasdaq.

Shares of this class outstanding were 42,618,165. During the past three months, Kreitzer sold 3,316 shares for 88239.00 on April 15, 2026 and 45,422 shares for 1347066.00 on April 27, 2026.

Positive

  • None.

Negative

  • None.
Shares to be sold 33,605 shares Proposed sale of MapLight voting common stock
Aggregate market value 1273966.00 Planned sale of 33,605 shares of MapLight voting common stock
Shares outstanding 42,618,165 shares Number of MapLight voting common shares outstanding
Prior sale 1 3,316 shares for 88239.00 Sale of MapLight voting common stock on 04/15/2026
Prior sale 2 45,422 shares for 1347066.00 Sale of MapLight voting common stock on 04/27/2026
Approximate sale date 07/15/2026 Planned date for sale of 33,605 shares on Nasdaq
Restricted stock unit settlement financial
"MapLight voting common stock | 07/15/2026 | Restricted stock unit settlement"
aggregate market value financial
"33605 | 1273966.00 | 42618165 | 07/15/2026 | Nasdaq"
Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.
Securities Sold During The Past 3 Months regulatory
"144: Securities Sold During The Past 3 Months"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What stock sale is disclosed for MapLight Therapeutics (MPLT)?

Anatol Kreitzer plans to sell up to 33,605 shares of MapLight voting common stock. The filing lists an aggregate market value of 1273966.00 and identifies Morgan Stanley Smith Barney LLC as the broker, with sales expected around July 15, 2026 on Nasdaq.

How many MapLight Therapeutics (MPLT) shares are outstanding in this notice?

The notice lists 42,618,165 shares of MapLight voting common stock outstanding. This figure provides context for the planned sale of 33,605 shares, indicating the filing relates to a relatively small portion of the total outstanding equity of this class.

What is the acquisition source of the shares Anatol Kreitzer plans to sell in MPLT?

The 33,605 MapLight voting common shares are shown as arising from a restricted stock unit settlement dated July 15, 2026. The issuer is identified as MapLight Therapeutics, Inc., with the transaction nature specifically described as a restricted stock unit settlement.

What prior sales did Anatol Kreitzer report for MapLight Therapeutics (MPLT)?

During the past three months, Kreitzer reported selling 3,316 shares for 88239.00 on April 15, 2026. He also sold 45,422 shares for 1347066.00 on April 27, 2026, both transactions involving MapLight voting common stock.

Which broker is handling the planned MapLight Therapeutics (MPLT) share sale?

The planned sale of 33,605 shares of MapLight voting common stock will be handled by Morgan Stanley Smith Barney LLC. The broker’s address is given as 1 New York Plaza, 8th Floor, New York, NY 10004, and the shares are expected to trade on Nasdaq.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature